MedTrace Logo

ADO-5030 in Bronchoconstriction Challenge, Phase 1b

NCT07281274 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-22

No results posted yet for this study

Summary

This is a Phase 1 study to learn about the safety and pharmacokinetics of the study drug in patients with asthma and whether the study drug has effect during a respiratory challenge.

Conditions

  • Asthma (Diagnosis)

Interventions

DRUG

ADO-5030

Single oral dose of ADO-5030.

Sponsors & Collaborators

  • University of Virginia

    collaborator OTHER

  • Adovate

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-06-01
Completion
2026-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07281274 on ClinicalTrials.gov